Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?  by Kloke, Heinrich J. et al.
PERSPECTIVES IN RENAL MEDICINE
Antihypertensive treatment of patients with proteinuric renal
diseases: Risks or benefits of calcium channel blockers?
HEINRICH J. KLOKE, AMANDA J. BRANTEN, FRANS T. HUYSMANS, JACK F. WETZELS
Division of Nephrology, Department of Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands
Antihypertensive treatment of patients with proteinuric renal diseases:
Risks or benefits of calcium channel blockers? In patients with proteinuric
renal diseases the rate of progression of renal insufficiency is determined
by the level of blood pressure and proteinuria. It has been demonstrated
that strict blood pressure control with angiotensin converting enzyme
(ACE)-inhibitors or beta-blockers, aimed at reaching values below 130/80
mm Hg, attenuates the deterioration of renal function. In general, the
beneficial effects of these drugs are reflected in a parallel lowering of
proteinuria. Calcium channel blockers are effective antihypertensive
drugs, however, their safety in patients with proteinuric renal diseases and
renal insufficiency may be questioned because of reported untoward
effects on urinary protein excretion. The present review discusses the
potential benefits and risks of calcium channel blockers (CCBs) in the
treatment of patients with renal diseases. To this end we have evaluated
the effects of these drugs in animal models of progressive renal injury. In
these animal models adverse effects of CCBs have been reported which
are attributed to an impairment of autoregulation. In patients with
proteinuria, the dihydropyridine CCBs do not lower proteinuria despite a
reduction of blood pressure. Studies on the effects on the course of renal
function are limited, however, the available data do suggest that this class
of CCBs may be less advantageous than other antihypertensive drugs, thus
arguing against the use of these agents as first-line drugs in patients with
proteinuric renal diseases. Information on the effects of the non-dihydro-
pyridine CCBs is limited to a small number of studies in patients with
diabetic renal disease. Although the data suggest that these classes of
CCBs might be more beneficial, more studies are needed, particularly in
patients with non-diabetic renal diseases, before founded conclusions can
be reached.
In patients with proteinuric renal diseases and renal insuffi-
ciency, renal function almost invariably worsens, a process that is
independent of the activity of the original renal disease [1]. More
than a decade ago Brenner, Meyer and Hostetter proposed the
hypothesis that glomerular hypertension resulting in glomerulo-
sclerosis is the final common pathway in this progression of renal
diseases [2]. Their hypothesis was mainly based on experimental
work in the rat remnant kidney model. Lowering of systemic, and
in particular glomerular, pressure by ACE inhibitors or low
protein diets ameliorated glomerulosclerosis and retarded renal
insufficiency. According to this theory proteinuria is a mere
reflection of glomerular pressure or glomerular injury. More
recently, the focus has shifted to the role of tubulointerstitial
injury in progressive renal diseases [3]. Proteinuria is no longer
considered just an innocent bystander, but rather is held respon-
sible for tubular cell injury and ensuing interstitial damage [4–7].
In humans, both hypertension and proteinuria determine the
rate of progression of renal insufficiency [8–10]. This was recently
confirmed in the largest prospective study to date, that is, the
Modification of Diet in Renal Disease (MDRD) study [11, 12].
The rate of decrease of glomerular filtration rate was highest in
patients with proteinuria. Furthermore, in this particular group of
patients antihypertensive treatment was most effective in inhibit-
ing the loss of GFR. In the MDRD study, the achieved systolic
blood pressure rather than the diastolic blood pressure correlated
best with the extent of renal protection. Of note, renal function
was best preserved in patients who achieved very low blood
pressures: lowering of blood pressure from normal levels of 135/85
mm Hg to “below normal” levels of 125/75 mm Hg was associated
with a preservation of renal function. As a consequence, patients
with proteinuric renal diseases will need effective antihypertensive
treatment.
Calcium channel blockers (CCBs) are effective antihyperten-
sive drugs also in patients with renal failure, who are generally
considered to be relatively resistant to antihypertensive treatment
[13]. On top of their antihypertensive efficacy, calcium channel
blockers do have other advantages: unlike other vasodilating
drugs they do not cause renal sodium and water retention [14],
and in contrast to ACE inhibitors they do not cause hyperkalemia.
However, at present it is unclear whether patients with renal
diseases will actually benefit from treatment with calcium channel
blockers. Doubt has been raised because the effects of calcium
channel blockers in animal models of progressive renal failure
have been controversial [15]. Thus far, most studies in humans
have concentrated on the effects of calcium channel blockers on
proteinuria, a surrogate marker of present and future renal injury.
In some of these studies untoward effects on proteinuria have
been reported [16–19], which has increased the uncertainty about
the use of this class of drugs.
It is our aim to provide an overview of the effects of the
different classes of CCBs in animal models of progressive renal
disease, and to discuss the relevance of these data for the human
situation. Furthermore, we have evaluated the effects of CCBs on
proteinuria and renal function in humans. Based on data from the
literature and our own experience, our view on the potential role
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of CCB in the treatment of patients with renal diseases and
proteinuria is presented.
CALCIUM CHANNEL BLOCKERS: CLASSES AND
MECHANISM OF ACTION
Calcium is an important intracellular messenger [20]. Influx of
calcium into cells is partly mediated by so-called voltage operated
calcium channels, which are classified according to their activation
characteristics in L, T, N, and P type channels [21]. The N, P, and
L channels are high-voltage channels. Both the N-type and P-type
channels are largely restricted to neurons and play a role in
neurotransmitter release and long-term depression of Purkinje
cells, respectively. The N and P channels are specifically inhibited
by v-conotoxin and v-agatoxin-IVA, respectively. Classical cal-
cium channel blockers do not bind to these channels. The L-type
channels are expressed in various tissues such as skeletal muscle,
heart, smooth muscle, endocrine cells and some neurons [22].
L-type channels are involved in the cardiac action potential and
the contractility of cardiac and vascular smooth muscle. Studies of
these channels have been facilitated by the development of the
various classes of calcium channel blockers that specifically bind
to these calcium channels. The T-type channel is a low-voltage
channel that has no specific blocker, which has hampered the
study of this channel [23]. The T-type channel has been implicated
in repetitive firing and pacemaker activity in heart and neurons.
Recently, it was suggested that the T-type channel may be
involved in angiotensin II-mediated aldosterone release [24, 25].
To date, three classes of calcium channel blockers have been
widely used in clinical practice: the dihydropyridines (DHP; such
as nifedipine, felodipine, amlodipine, nitrendipine, nicardipine,
isradipine), the phenylalkylamines (verapamil), and the benzo-
thiazepines (such as diltiazem). All these CCBs interact with the
L-type calcium channel, and different binding sites for the various
classes of CCBs have been identified [21]. Recently, a new class of
CCB has been introduced. The prototype mibefradil, a tetraline
derivative, blocks not only L- but also T-type calcium channels
[26]. However, the clinical relevance of this T-channel blocking
property is as yet unclear. All classes of CCBs have in common
that they block voltage-operated calcium channels. Calcium chan-
nel blockers reduce blood pressure primarily by vasodilation, as a
result of the blockade of calcium channels in vascular smooth
muscle cells. However, the various CCBs clearly differ in their
tissue selectivity, probably because of the differences in binding
sites [21]. The DHP act primarily on vascular smooth muscle cells,
whereas verapamil and diltiazem also influence the cardiac action
potential. Also, the various CCBs differ in their influence on
myocardial cells, and thus in negative inotropic effects on the
heart. All these differences determine the clinical use of CCBs,
such as in arrhythmia or hypertension.
CALCIUM CHANNEL BLOCKERS: ANIMAL MODELS OF
RENAL INJURY
Tables 1 and 2 summarize the studies that have evaluated the
particular effects of calcium channel blockers in animal models of
progressive renal disease [27–60]. It is evident that these studies
are quite heterogeneous because of the use of 14 different animal
models, both diabetic and non-diabetic, the type and dose of the
calcium channel blocker, the interval between the induction of
renal injury and the start of treatment, and the duration of
follow-up have been examined. To assess the protective potential
of the CCBs, most studies have relied on proteinuria and glomer-
ular histological abnormalities (mostly glomerulosclerosis). Less
frequently, loss of renal function and survival have been used. The
available data suggest that effects on proteinuria and glomerulo-
sclerosis are closely linked; in all studies in which a reduction of
proteinuria was observed during treatment with a CCB, this effect
was paralleled by a decrease of glomerulosclerosis, whereas in
studies in which proteinuria was not influenced favorably, the
severity of glomerulosclerosis did not differ between treatment
groups and control groups.
Summarized in Table 1 are 18 studies reporting a positive and
protective (that is, a decrease of proteinuria or glomerulosclero-
sis) effect of the CCBs, whereas the other 15 studies that report
either no benefit or even harmful effects are summarized in Table
2. In 17 studies (including 10 studies that could not demonstrate
a benefit of the CCBs) the effects of ACE inhibitors were also
studied, and in all but two studies in which ACE inhibitors were
used, they offered protection [27–29, 40, 41, 43, 46, 48–50, 52, 54,
56–60].
At first sight, the results of the various studies seem rather
conflicting. How can we reconcile these animal data?
Role of systemic blood pressure
Mechanistically speaking, one important aspect to consider are
the effects of the calcium channel blockers on systemic and
glomerular pressures, probably the best studied factors proven to
be involved in progressive renal injury. Figure 1 illustrates the
decrease in proteinuria and the decrease in systemic blood
pressure reported by the various investigators. Clearly, there is no
simple relationship between the antiproteinuric effects and the
blood pressure lowering effects. Two explanations can be offered
for the absence of a relationship. At one hand, systemic blood
pressure might not be a good reflection of intraglomerular
pressure, since the relationship between systemic blood pressure
and glomerular pressure is dependent on the resistances of the
afferent and efferent arterioles (vide infra). On the other hand,
differences in methods may be involved. In most animal studies
the number of blood pressure measurements is limited and
performed by techniques that by themselves can influence blood
pressure. Some investigators measure blood pressure by the tail
cuff method, resulting in increased blood pressures as a result of
the needed restraint, whereas others measure blood pressure
intra-arterially in anesthesized animals, resulting in a falsely low
blood pressure. The impact of blood pressure measurements has
been elegantly studied by Bidani et al [61, 62]. These investigators
measured blood pressure almost continuously (every 10 min) with
a telemetric device. They observed that blood pressures were
quite variable, and labile, especially in the rat remnant kidney
model. The continuously measured blood pressures differed from
the blood pressures measured by the other techniques. When
looking at renal injury, it became evident that glomerulosclerosis
correlated highly significantly with the average systolic blood
pressure and with the frequency of systolic blood pressures above
140 mm Hg. Based on these data, one explanation for the
observed failure of CCBs to protect against renal injury might be
that these drugs fail to consistently lower blood pressure over a 24
hour period [53]. However, this explanation probably does not
hold for all studies. One example is the study of Remuzzi et al,
who compared the calcium channel blocker nitrendipine and the
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ACE inhibitor lisinopril. Blood pressure was measured four to five
times daily. Despite equal lowering of blood pressure, nitrendip-
ine was clearly less effective than lisinopril [56].
Role of glomerular capillary pressure and renal autoregulation
The work of Bidani and coworkers points to another possible
explanation for the unexpected ineffective or even detrimental
effects of calcium channel blockers. These investigators have
shown that in their models of renal injury an enhanced glomerular
transmission of the systemic hypertension plays a major role in the
induction and progression of renal injury. It is known that the
transmission of the systemic blood pressure to the glomerulus is
dependent on the resistance of the afferent arteriole. Under
normal circumstances glomerular pressure does not increase in
Table 1. Effects of calcium channel blockers (CCBs) in animal models of progressive glomerulosclerosis: Overview of studies demonstrating a
beneficial effect of the CCBs on proteinuria and/or glomerulosclerosis
Ref.
no.
Exper.
model
Start of
treatmenta
Duration
of therapy Drugs
SBP end of
the study
MAP end
of the study
Proteinuria
end of the
studyb
Histology
Additional remarksGS TI
[27] UniNx-Rats 0 6–8 weeks Nifedip. 122 6 7e 106 6 2e 37 6 8e 2e NA
DOCA-salt vs Untr. 192 6 6 139 6 4 77 6 12
[28] UniNx-SHR 0 36 weeks Nifedip. ;175e 126 6 3e 37 6 5e 2e NA
vs Untr. ;220 172 6 4 70 6 10
[29] RK-MW 0 4–8 weeks Nifedip. ;130e 136 6 5e 18 6 3e 2e NA Vg 2
Rats vs Untr. ;245 169 6 12 73 6 8
[30] RK 0 max 20 Nisoldip. 147 6 20e NA 68 6 60c 2 5 Survival 1e
Rats weeks vs Untr. 237 6 20 NA 109 6 45c
[31] RK-Fischer 1 day 12 weeks Manidip.
Rats 0.0004% 141 6 9 NA ;90e 2e 2e
0.002% 128 6 6e NA ;55e 2e 2e
0.01% 129 6 8e NA ;85e 2e 2e
0.05% 132 6 6e NA ;175e 1e 1e
vs Untr. 146 6 6 NA ;130
[32] RK-SHR 0 10 weeks Amlodip. 237 6 23e NA ;130e 2e 2e Arter. scler. 2e
High salt vs Untr. 287 6 5 NA ;361
[33] RK-SD 2 weeks 12 weeks Verapamil NA ;131 294 6 67 2e 5 Calcium content 2e
Rats vs Untr. NA ;142 354 6 42 Survival 1e
[34] RK-SD 1 week 4–6 weeks Anipamil NA 144 6 36e 95 6 22 NA NA Calcium content 2e
Rats vs Untr. NA 192 6 35 126 6 35 Survival 1e
[35] SHR at age of 6 months Felodip. NA 146 6 4e 15 6 2e 2e NA
15 months vs Untr. NA 184 6 10 34 6 2
[36] SHR at age of 8 weeks Nicardip. 205 6 5e NA 4.7 6 0.2c,e NA NA Glom./vascular
12 weeks vs Untr. 260 6 5 NA 6.0 6 0.2c alterationse
[37] SHR at age of 20 weeks Efonidip. ;210e NA ;60e 2e 2e Arter.scler. 2e
7 weeks vs Untr. ;240 NA ;400
[38] SD-rats 7 days before 3 weeks Manidip.
Heymann induction 2 low 111 6 5 NA 59 6 13d 5 NA
2 high 98 6 12 NA 47 6 9de 5 NA
vs Untr. 105 6 6 NA 62 6 8d
[39] SD-rats during 3 months Benidip.
PAN 1 PS induction 2 low ;112 NA 3.5 6 0.9c 5 5
2 high ;106e NA 2.1 6 0.4c 2 2
vs Untr. ;118 NA 5.3 6 1.6c
[40] UniNx-Diab 0 1 year TA-3090 NA 116 6 5 ;2e Foc.2 1 Vg 2e
[41] Dogs vs Untr. NA 126 6 7 ;32 Glob.1
[42] Diab-Wistar 1 week 20 weeks Diltiazem ;125e NA ;2e NA NA
Rats vs Untr. ;145 NA ;44
[43] UniNx-Diab 1 week 12 weeks Benidip. ;135e NA 30 6 4e NA NA
WKY Rats vs Untr. ;160 NA 59 6 7
[44] Subtot.Nx 48 hours 8 weeks Nifedip. 98 6 23e NA NA 2e 5 Vascular damage–e,
SD-Rats vs Untr. 119 6 9 NA NA mesangial
proliferation–e
[45] SHR at age of 3 months Nifedip. 144 6 21e NA NA 2e 2e Tubular atrophy 2e,
6 months vs Untr. 193 6 39 NA NA Vg 1e
Abbreviations are: GS, glomerulosclerosis; TI, tubulointerstitial injury; Foc., focal sclerosis; Glob., global sclerosis; 2, decrease; 5, unchanged; 1,
increased compared to controls; NA, not available; ;, approximately; UniNx, uninephrectomy; DOCA-salt, deoxycorticosterone acetate with high salt;
SHR, spontaneously hypertensive rats; RK-MW, remnant kidney-Munich Wistar; SD, Sprague Dawley; PAN, puromycin aminonucleoside; PS,
protamine sulfate; Diab, Diabetic; WKY, Wistar Kyoto; Subtot.Nx, subtotally nephrectomized; Vg, glomerular volume; Arter. scler., arterio(lo)sclerosis;
Glom., glomerular. All drug-names abbreviated as “dip.” are dihydropyridine CCBs and have to end as “-dipine.”
a Start of treatment represents the interval between the induction of injury and the start of therapy. For SHR rats time of birth is considered as the
time of induction of injury.
b Proteinuria is expressed as mg/24 h, mg/24 h/100 mg bodyweightc, or mg/mg creatinined
e P , 0.05 vs Untr. (5untreated); means 6 SEM or SD are given
Systolic blood pressure (SBP) and mean arterial pressure (MAP) in mm Hg.
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parallel with an increase of systemic blood pressure. Indeed, such
an increase of glomerular pressure is prevented by the so-called
autoregulatory response, mediated by afferent vasoconstriction.
In the remnant kidney model renal autoregulation is attenuated,
and defective autoregulation correlates with injury. A low protein
diet that restores autoregulation attenuates renal injury [63].
At this point it is important to realize that the afferent arteriole
is the renal vessel most responsive to CCBs. Studies in the
hydronephrotic rat kidney, a model that allows direct visualization
of the glomerular vessels, have demonstrated that CCBs prefer-
entially cause dilation of the afferent arteriole [64, 65]. Indeed,
CCBs are the only antihypertensive drugs that impair renal
Table 2. Effects of calcium channel blockers (CCBs) in animal models of progressive glomerulosclerosis: Overview of studies demonstrating no
beneficial effect of the CCBs on proteinuria and/or glomerulosclerosis
Ref.
no.
Exper.
model
Start of
treatmenta
Duration
of therapy Drugs
SBP end of
the study
MAP end
of the study
Proteinuria
end of the
studyb
Histology
Additional remarksGS TI
[46] RK-Wistar 5 weeks 15 weeks Verapamil 158 NA 58.2cd 1d NA Survival 2d
Rats vs Untr. 175 NA 17.2c
[47] RK-Wistar 5 weeks 16 weeks Verapamil
Rats 2 low 162 156 6 7 20.7c 5 5
2 high 140d 124 6 3 29.4c 5 1 Kidn.weight 1d
vs Untr. 185 180 6 8 13.8c Survival 2d
[48] RK-postsalt 4 days 2 weeks TA-3090 ;160d 158 6 7 ;200 2d NA Vg 2d
SD-Rats vs Untr. ;230 177 6 9 ;200
RK-postsalt 4 days 4 weeks TA-3090 ;140d NA 333 6 64d 5 NA Cholesterol 1d,
SD-Rats vs Untr. ;215 NA 180 6 23 Survival 1
[49] Adriamycine Diltiazem
SD-Rats 10 weeks 28 weeks 2 wk 10 NA 122 6 6d max 450d 5 NA
24 weeks 14 weeks 2 wk 24 NA 133 6 5d ;230 2d NA Mesangial
vs Untr. NA 154 6 7 ;190 expansion 2d
[50] Subtot.Nx 1 week 5 weeks Felodip. ;130d 104 6 6d 221 6 35d 5 NA
SD-Rats vs Untr. 176 6 7 139 6 5 84 6 22
[51] 2K-1C Rats 6 weeks 6 weeks Nitrend.
vs Untr.
183 6 5
192 6 5
NA
NA
163 6 55d
19 6 9
1d 5 Vg1, Tubular
atrophy &
dilation 1
[52] 2K-1C Rats 8 weeks 5 weeks RO405967 160 6 2d NA 139 6 44 5 5 Vascular lesions 2,
vs Untr. 216 6 13 NA 83 6 35 Vg 1
[53] UniNx-Rats 0 8 weeks Amlodip. ;145d 112 6 5d ;100 5 NA Vg 5
DOCA-salt vs Untr. ;175 146 6 6 ;105
UniNX-SHR 0 5 months Amlodip. ;150d 136 6 2d ;80d 5 NA Vg 5
vs Untr. ;235 170 6 8 ;55
[54] RK-Rats 1 week 7 weeks Nifedip. ;130 NA ;68 5 NA Vg 5
vs Untr. ;190 NA ;65
[55] UniNx-SHR 0 12 weeks Manidip.
2 low 213d NA 55 6 4 5 5
2 high 160d NA 59 6 6 5 5 Mesangial
vs Untr. 219 NA 54 6 3 proliferation 2d
[56] MWF/Ztm At age of 6 months Nitrend. 140 6 11d NA 271 6 36d 1; NS 5 Vg 5
Rats 10 weeks vs Untr. 170 6 8 NA 321 6 54
[57] Diabetic 0 16 weeks Lacidip. 131 6 5d NA 18 6 1 NA NA
SHR Rats vs Untr. 172 6 10 NA 29 6 1
[58] Diabetic 0 4–6 weeks Lacidip. 117 6 5d NA 16 6 6 NA NA
SD-Rats vs Untr. 142 6 5 NA 29 6 12
0 12 months Lacidip. 122 6 6d NA 338 6 66 5 5
vs Untr. 155 6 9 NA 355 6 98
[59] UniNx-Diab. 0 8 weeks Nifedip. NA 106 6 2d NA NA NA
MW-Rats vs Untr. NA 118 6 5 NA
0 8 months Nifedip. 118 6 4d NA 136 6 26 5 NA Vg 5
vs Untr. 145 6 5 NA 113 6 18
[60] UniNx-Diab. 1 month 2 months Verapamil 114 6 2 NA 58 6 10 NA NA
SD-Rats vs Untr. 131 6 2 NA 71 6 18
Abbreviations are: GS, Glomerulosclerosis; TI, Tubulo-interstitial injury; 2, decrease; 5, unchanged; 1, increased compared to controls; NA, Not
available; ;, approximately; NS, not significant; RK, remnant kidney; SD-rats, Sprague-Dawley; Subtot.Nx, subtotally nephrectomized; 2K-1C, two
kidney-one clip model; UniNx, Uninephrectomized; DOCA-salt, Deoxycorticosterone acetate with high salt; SHR, Spontaneously hypertensive rats;
MWF/Ztm-rats, a model of spontaneous glomerular injury; MW, Munich-Wistar rats; Vg, Glomerular volume. All drug-names abbreviated as “-dip.”
are dihydropiridine CCB’s and have to end as “-dipine”.
a Start of treatment represents the interval between the induction of injury and the start of therapy; for SHR rats time of birth is considered as the
time of induction of injury.
b Proteinuria is expressed as mg/24 hr, cor mg/mg creatinine
d P , 0.05 vs. Untr. (5untreated); means 6 SEM or SD
Systolic blood pressure (SBP) and mean arterial pressure (MAP) are in mm Hg.
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autoregulation [66]. Both verapamil (a fenylalkylamine) and the
dihydropyridines nifedipine and nicardipine attenuate the auto-
regulatory response in dogs [67, 68]. Such an impairment of
autoregulation has been confirmed in rats for nifedipine and
verapamil [69, 70]. Griffin, Picken and Bidani have followed up on
these ideas. In the rat remnant kidney model, they demonstrated
that nifedipine further impairs the already somewhat disturbed
autoregulatory response [54]. In their model they have consis-
tently found a perfect correlation between systolic blood pressure
and the degree of glomerulosclerosis (Fig. 2). In fact, the data
points of untreated rats as well as of rats treated with either an
ACE inhibitor or triple therapy could all be fitted to the same
curve describing this relationship. For rats treated with nifedipine
a correlation was also found between blood pressure and glomer-
ulosclerosis; however, the curve describing this relationship was
shifted to the left, indicating that at a given level of blood pressure
glomerular injury is higher during treatment with the CCB
nifedipine (Fig. 2). Recent studies, as yet only published in
abstract form, confirm the harmful effects of autoregulatory
disturbances. It was demonstrated that the relationship between
glomerulosclerosis and blood pressure is also shifted to the left by
felodipine and by verapamil [71]. Furthermore, verapamil atten-
uated the protective efficacy of a low protein diet, again suggest-
ing a role for interference with autoregulation by this drug [72].
One of the abovementioned abstracts suggested that diltiazem
might not impair autoregulation [71]. However, a closer look at
the data of the latter study reveals that diltiazem had no effect at
all, not even on blood pressure, suggesting that the dose used was
too low. Other animal data indicate that diltiazem will also cause
an increased transmission of the systemic blood pressure to the
glomerulus. Diltiazem, like the other classes of CCBs, preferen-
tially causes afferent arteriolar vasodilation [73, 74]. In diabetic
beagle dogs Brown et al observed a definite trend towards
impairment of autoregulation by the benzothiazepine TA-3090
[40, 41].
In case of an impairment of the autoregulatory response one
would expect that CCBs can only be protective if blood pressure
is lowered to such an extent that the impairment of autoregulation
is compensated for. Indeed, in a number of the studies in Table 1,
all showing renal protection by the CCBs, a major reduction in
blood pressure was achieved of more than 25% [27–30, 45]. When
the blood pressure is very high, at a level above the autoregulatory
range, one would expect that more modest reductions in blood
pressure also offers protection. This assumption is supported by a
few studies in which control blood pressures were very high and
reductions of a lesser degree (10 to 25%) were accompanied by
antiproteinuric effects and decreased morphologic damage [32,
35–37].
The relationship between the degree of blood pressure reduc-
tion and glomerular injury is also demonstrated when analyzing
consecutive studies performed by the same investigators in the
same model. Wenzel and coworkers have used the two kidney one
clip model of hypertension [51, 52, 75]. Harmful effects (such as
increased proteinuria and glomerulosclerosis) were observed dur-
ing treatment with nitrendipine, which lowered blood pressure by
only 5% [51]. Mibefradil, used in the same renal model, lowered
blood pressure by 26% and did not lower proteinuria nor atten-
uate glomerulosclerosis [52]. When nitrendipine was combined
with enalapril the renal effects compared favorably with enalapril
alone: proteinuria and blood pressure were fully normalized, and
complete renal protection was obtained [75]. Brunner et al
studied the effects of different dosages of verapamil in the rat
remnant kidney model, and found that an intermediate dose
resulted in minor effects on blood pressure, more proteinuria and
more glomerulosclerosis. The higher dose, which lowered blood
pressure more effectively, did not significantly increase protein-
uria nor glomerulosclerosis [46, 47]. Dworkin used both nifedi-
pine and amlodipine in the uninephrectomized DOCA-salt rat
model and in the uninephrectomized spontaneously hypertensive
rat (SHR) rat [27, 28, 53]. The protective renal effects noticed
Fig. 2. Correlation of glomerular injury with overall averaged systolic
blood pressure in the rat remnant kidney model. Figure adapted from
Griffin et al [54]. Curve A describes the correlation for rats either
untreated or treated with the ACE inhibitor enalapril. Curve B describes
the relationship for nifedipine treated rats. Clearly, the slope is shifted to
the left, indicating an increased susceptibility to glomerular injury in the
nifedipine group. Curve C is a hypothetical curve, based on the assump-
tion that the calcium channnel blockers might be protective via other
mechanisms than influencing blood pressure.
Fig. 1. Relationship between the change in blood pressure and the
change of proteinuria during treatment with calcium channel blockers in
animal models of glomerulosclerosis. Data are derived from the studies in
Tables 1 and 2.
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during nifedipine were not seen during amlodipine. When the
numbers presented in these studies are compared, nifedipine
lowered blood pressure more effectively than amlodipine in both
models [27, 28, 53]. Altogether, these observations might provide
an explanation for the controversial results of the studies pre-
sented in Tables 1 and 2.
As mentioned above, defective autoregulation will result in an
increased transmission of the systemic blood pressure to the
glomerulus. We assume that the effects of CCBs on renal injury
are related to the changes in glomerular pressure. Unfortunately,
measurements of intraglomerular pressure have been performed
in only seven studies [27–29, 40, 53, 56, 59]. In six studies
intraglomerular pressure was unaffected by the calcium channel
blocker despite blood pressure reduction, results that are compat-
ible with the abovementioned adverse effects on autoregulation
[27, 29, 40, 53, 56, 59]. Only one study observed a decrease of
glomerular capillary pressure during treatment with a CCB [28].
In this latter study, nifedipine was used in the uninephrectomized
SHR rat, which protected the animal against the development of
glomerulosclerosis.
Admittedly, in three of the abovementioned studies the CCBs
lowered proteinuria and attenuated glomerulosclerosis, despite
the unchanged glomerular capillary pressure [27, 29, 40]. The
latter studies suggest that progression of renal failure cannot only
be explained by increased systemic or glomerular pressure. Other
mechanisms may be involved, and the effects of CCBs on these
mechanisms must be considered. Alternative pathways of protec-
tion by CCBs may cause a downward shift of the curve relating
glomerulosclerosis to blood pressure (Fig. 2), and thus balance or
even outweigh the impact of the impairment of autoregulation.
Role of glomerular hypertrophy
Some investigators have stressed the role of glomerular hyper-
trophy. Indeed, in some experimental models it has been shown
that hypertrophy is required for injury to occur [76–78]. Preven-
tion of glomerular hypertrophy averts renal injury and glomeru-
losclerosis. Calcium channel blockers are able to attenuate kidney
hypertrophy after uninephrectomy [27–29]. Indeed, Dworkin sug-
gested that CCBs afford protection in various models by way of
limiting hypertrophy independently from effects on glomerular
pressure [79]. However, such an effect on hypertrophy is not
uniformly observed. It has been demonstrated that CCBs did not
lower kidney weight after uninephrectomy [53, 80] or even
induced an increase of glomerular hypertrophy [45, 51, 52]. These
differences in hypertrophic response may be related to the timing
of the administration of the CCB in relation to the induction of
renal injury and the onset of the hypertrophic response.
Role of timing of treatment
One factor that may explain the differences in outcome of the
various studies is the interval between the induction of injury and
the start of the treatment. In most studies in Table 1 (the
protective studies) treatment was started immediately after induc-
tion of the injury, whereas in the negative studies the start of
treatment was often delayed [46, 47, 51, 52]. The importance of
the timing of the start of treatment is highlighted by the studies of
Dworkin. In his earlier studies employing the rat remnant kidney
model it was demonstrated that nifedipine started at the time of
injury afforded complete protection [29]. However, when treat-
ment was started four weeks after the induction of injury,
nifedipine was no longer protective [81]. The timing of drug
treatment might also explain the beneficial effects of CCBs in
models of Heymann nephritis and aminonucleoside nephrosis [38,
39]. It seems quite possible that by administering the drugs before
the induction of injury one affects the induction phase, thus
limiting the harmful effects of puromycin, or limiting the immune
response in case of the Heymann model.
Other mechanisms of renoprotection
It has been suggested that CCBs may protect against progres-
sive renal injury by diminishing cellular uptake of calcium and
preventing calcinosis [82]. Such an effect could explain the results
of Harris et al and Jarusiripitat et al, who observed better survival
in remnant kidney rats treated with verapamil or anipamil [33, 34].
These studies are remarkable because of the high mortality (due
to renal failure) in the untreated control groups, suggesting that in
these particular studies additional mechanisms of renal injury
have been operative.
Other beneficial effects of CCBs are the reduction of vascular
damage, particularly in models of severe hypertension [32, 36, 37,
44, 52], and attenuation of mesangial proliferation [44, 49, 55].
The relevance of this latter finding is unclear, however, since in
the study of Amann et al the effects on mesangial cell prolifera-
tion were not matched by protective effects on the podocyte or the
tubulointerstitium [44]. An untoward effect on tubulointerstitial
fibrosis was noted by Gaber et al, who observed more tubuloin-
terstitial injury during treatment of diabetic beagle dogs with a
diltiazem derivative [40].
Calcium channel blockers might be protective in specific con-
ditions where afferent vasoconstriction and ischemic injury are
important. Administration of the nitric oxide (NO) synthase
inhibitor L-NMMA in rats induces hypertension, proteinuria, and
progressive renal failure [83]. Renal histological damage is char-
acterized by glomerular collapse, interstitial expansion, and glo-
merulosclerosis [84]. In this model nifedipine largely prevented
these abnormalities without having a major influence on renal
hemodynamics or blood pressure [84]. The use of the immuno-
suppressive drug cyclosporine is associated with nephrotoxicity,
which is attributed to constriction of the afferent arteriole [85].
Experimental data suggest that calcium channel blockers may be
effective in reducing cyclosporine-induced renal damage [85].
CALCIUM CHANNEL BLOCKERS: HUMAN STUDIES
Effects on proteinuria
The development of end-stage renal disease (ESRD) is the best
and most definitive end point for studies evaluating the effects of
antihypertensive drugs on renal function deterioration. However,
controlled studies in humans on the effects of CCB and the risk of
developing ESRD are virtually lacking. It has been demonstrated
that systemic and more importantly glomerular pressure are
important factors in the progression of renal failure [1]. Protein-
uria may be a reflection of intraglomerular pressure, but it may
also induce renal damage on its own by causing tubulointerstitial
injury [3, 7]. Indeed, recent studies have demonstrated that
proteinuria is an important determinant of renal function deteri-
oration [9], and that the lowering of proteinuria precedes and
predicts a subsequent decrease in the rate of renal function
deterioration [12, 86, 87]. Therefore, proteinuria is frequently
used as a surrogate end point in studies investigating potentially
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beneficial effects of antihypertensive drugs on the progression of
renal disease. Thus, it seems quite relevant to critically assess the
effects of CCBs on proteinuria in patients with renal disease and
overt proteinuria. We performed a Medline database search and
screened recent articles and reviews for cross references. From
these, 69 full length articles were selected in which patients were
treated in randomized or non-randomized fashion for at least one
week with a calcium channel blocker [16, 19, 88–155]. To be
included in the analysis both data on blood pressure and protein-
uria had to be provided. Because of differences in prognosis,
etiology, and treatment effects, we were particularly interested in
patients with a high proteinuria (.500 mg/24 hr). Since the
number of studies in this patient group was low, non-randomized
studies were also included. Some studies provided data on two or
more groups of patients treated with a CCB, and these were
analyzed separately. Consequently, the total number of treatment
groups (Table 3) exceeds the number of studies. In 46 randomized
studies data on the effects of ACE inhibitors were also reported
that were used for comparison. Relevant data were gathered from
these publications. To make data comparable we used the mean
arterial pressure as given by the authors, or MAP was calculated
as diastolic pressure plus one third of the pulse pressure. Since
many papers only provided data on albuminuria, we have used this
as the relevant parameter. In case data were given as total urinary
protein excretion, we calculated albuminuria from proteinuria by
using an appropriate correction factor [156]. These correction
factors are probably only a rough estimate. However, conversion
of proteinuria to albuminuria was only needed to assign patients
to a group with low albuminuria (,500 mg/24 hr) or a group with
high albuminuria (.500 mg/24 hr). In the high albuminuria group
only 17 studies reported total protein excretion rates. The lowest
value in these studies was 1330 mg/24 hr. Even when total protein
excretion was divided by a factor 2.0 instead of 1.2, this group of
patients still belonged to the high albuminuria group. In the low
albuminuria group only three studies reported total protein
excretion rates. The highest value of these three studies was 340
mg/24 hr. Therefore, any reasonable correction factor would not
change the classification of this patient group. Percent changes in
blood pressure and proteinuria were calculated from baseline or
from time controlled placebo values. Correlations were assessed
by determining the Spearman correlation coefficient. Weighed
means were calculated by the formula S(xi * ni/nt), where S is the
sum, xi is the value of a group, ni is the number of patients in that
group and nt is the total number of patients of all groups.
An overview of the treatment groups is given in the Table 3. It
is evident that most studies were done with DHP, in diabetic
patients and/or in patients with low albuminuria. Thus, informa-
tion on the effects of CCBs on proteinuria in patients with
non-diabetic renal disease and high albuminuria was limited to 11
studies with dihydropyridines (5 with nifedipine) and one with
verapamil.
The overall results of the various studies are summarized in
Figure 3, in which patient groups are divided according to the the
level of albuminuria, type of renal disease (diabetic vs. non-
diabetic) and the type of CCB used. Apparently, the results
obtained with DHP are quite heterogeneous. It has been sug-
gested that dihydropyridine CCB might be more effective in
diabetic patients [157, 158]; however, with all of the studies taken
together there was no difference in the response between diabetic
and non-diabetic patients. Dihydropyridines have some antipro-
teinuric effects in patients with low albuminuria, whereas almost
no effect is observed in patients with albuminuria .500 mg/24
hours. Since increases in proteinuria have been observed in
particular with the DHP nifedipine, we analyzed the data further
by dividing the DHP patients in two groups according the use of
nifedipine. Although proteinuria was seemingly less decreased by
nifedipine, the difference between the mean changes is not
impressive and is mainly due to the results of only one study in
which the use of a non-nifedipine DHP resulted in an unexpect-
edly high decline in proteinuria (Fig. 3). In diabetic patients
verapamil and diltiazem seem more effective than dihydropyri-
dines, although blood pressure reduction was also more pro-
nounced with these treatments. No pertinent data on the effects
of verapamil or diltiazem are available for non-diabetics. It is
evident that ACE inhibitors had a clear antiproteinuric effect in
all groups.
When combining data of all studies with DHP, only a very weak
correlation between the decrease in blood pressure and the
decrease in proteinuria was seen (r 5 10.2487, P , 0.05; Fig. 4).
A possible explanation for this is the fact that measurements of
blood pressure and proteinuria are not performed in parallel, and
measurements of blood pressure are done only at a single time
point. In this respect the short duration of action of the nifedipine
formulations used may be relevant. Urine collections were mostly
done during 24 hours. Six of all DHP treated groups reported
timed overnight urine collections. Timed urine collections by day
were reported in 13 of the 67 DHP groups. If one only considers
data from these 13 studies in which urine was collected over short
intervals by day, probably more closely related to the time of
blood pressure measurement, a significant correlation (r 5
10.8022, P , 0.01) is observed. The regression line suggests an
intercept far above zero. Figure 4 clearly demonstrates that when
blood pressure is only modestly reduced proteinuria increases,
whereas a greater reduction in blood pressure is needed to see a
decrease in proteinuria. In this respect, these data fit with the
findings of Griffin et al [54], describing the relation between blood
pressure and glomerular injury in rats after treatment with
nifedipine (Fig. 2).
One explanation for such an increase of proteinuria could be a
decreased tubular protein reabsorption. Calcium channel block-
ers, especially those of the DHP class, increase urinary sodium
and water excretion, partly by decreasing proximal tubular sodium
reabsorption [159, 160]. It has been suggested that dihydropyri-
dine CCBs might also block tubular protein reabsorption. Some
Table 3. Studies on the effects of calcium channel blockers on
proteinuria in humans
Nifedipine Other DHP Verapamil Diltiazem
Diabetic patients
Low albuminuria 12 (224) 17 (233) 4 (71) 0
High albuminuria 9 (104) 5 (52) 1 (8) 5 (62)a
Non-diabetic
patients
Low albuminuria 3 (63) 10 (174) 1 (10) 0
High albuminuria 5 (69) 6 (69) 1 (10) 0
Numbers of treatment groups are given (in brackets numbers of
patients). Abbreviation is DHP, dihydropyridines.
a In one of these studies eight patients were treated with verapamil, the
other 10 patients with diltiazem
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studies reported an increased excretion of urinary b2-microglobu-
lin, a marker of proximal tubular protein reabsorption, after
administration of nifedipine [115, 116, 161]. However, in one of
these studies the increase of the b2-microglobulin excretion was
not significant [116], and in another the increase was only 10%,
and may be explained by a period effect [115]. In a third study a
definite increase of b2-microglobulin excretion was parallelled by
an abrupt increase in urinary flow, suggesting that the increased
excretion was caused by a wash-out of urine [161]. Recently, in a
short-term study with a natriuretic dose of nifedipine we did not
find a change in urinary b2-microglobulin excretion either acutely
or after repeated administration during one week [126]. Overall,
the arguments in favor of an effect of DHP on tubular protein
reabsorption are weak.
It is tempting to speculate that the absence of an antiproteinuric
effect of dihydropyridine CCBs in patients with overt proteinuria,
like in animals, is explained by a disturbance of autoregulation
allowing enhanced transmission of the systemic blood pressure to
the glomerulus. In such a case the potentially beneficial effects of
blood pressure lowering are balanced or outweighed by the
increased transmission of pressure to the glomerulus due to the
afferent vasodilation. Other findings support this idea. In patients
with a nephrotic syndrome a high protein load acutely increased
proteinuria [162]. Co-administration of nifedipine further en-
hanced the proteinuria despite the observed small blood pressure
reduction of 4 mm Hg, suggesting more prominent afferent
glomerular vasodilation. The complexity of the interplay between
systemic blood pressure reduction and afferent glomerular arte-
riolar vasodilation is evident from the following example: ne-
phrotic patients were studied when adhering to a high protein diet
[66]. When using the high protein diet, verapamil lowered pro-
teinuria. The study was repeated during adherence to a low
protein diet, and the low protein diet preserved autoregulation. In
the latter case it can be expected that vasodilation of the afferent
arteriole will counteract the decrease of systemic blood pressure.
Indeed, during the low protein diet verapamil did not lower
proteinuria.
In our recent study in patients with renal disease we observed a
difference in proteinuria dependent on posture [126]. Nifedipine
increased proteinuria during standing or walking. Possibly this has
to be ascribed to higher norepinephrine levels during standing: if
nifedipine attenuates the effect of norepinephrine on the afferent
arterioles, systemic blood pressure will be transduced more easily
to the glomerulus, thereby enhancing the filtration of proteins.
The available data, admittedly limited to patients with diabetes,
suggest that there may be a difference in the antiproteinuric
effects of DHP versus non-dihydropyridine CCBs. One may ask if
differences between DHP versus verapamil or diltiazem can be
Fig. 3. Relative changes in albuminuria for groups treated with nifedipine (NIF), other dihydropyridines (DHP), verapamil (VER) or diltiazem (DIL)
and angiotensin converting enzyme inhibitors (ACEinh) in humans. Filled symbols indicate groups with diabetes, crosses indicate non-diabetic groups.
Bars in the Figure indicate weighed means. Relative changes in mean arterial pressure (MAP) are also given as weighed means. Low/high albuminuria
is less/more than 500 mg/24 hours.
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explained by differences in sodium intake. In general, the long-
term antihypertensive effects of DHP and verapamil are hardly
dependent on sodium intake [163–165]. One study reported on
the effects of low and high sodium intake during treatment with
nifedipine and diltiazem [94]. During nifedipine no effect on
urinary protein excretion rate was seen, whereas diltiazem de-
creased proteinuria only during low salt intake, despite a compa-
rable blood pressure reduction. Therefore, it is conceivable that
the antiproteinuric effect of the latter drug is mediated by an
effect on the renin-angiotensin system. However, studies using
DHP, diltiazem or verapamil in hypertensive patients did not
show a clear effect of these drugs on PRA in the long run [166,
167]. To our knowledge studies with these drugs on the effects on
PRA in patients with proteinuria are not available.
Thus far, no studies have been reported on the effects of the
new calcium channel blocker mibefradil on proteinuria. However,
we have preliminary data from a recently completed multicenter
study in patients with renal insufficiency and proteinuria who were
treated with either the new CCB mibefradil or nifedipine. When
compared to baseline values, obtained after withdrawal of antihy-
pertensive drugs such as ACE inhibitors, both drugs caused a
similar increase in proteinuria, whereas mibefradil was more
effective in lowering blood pressure.
Effects on the course of renal function
Several investigators have reported on the short-term effects of
CCB treatment on renal hemodynamics in patients with non-
diabetic renal disease. Within a one year period generally no
adverse effects on GFR or RPF are noted [96, 134]. However, the
time frame of such studies is too short to allow meaningful
conclusions. Only a limited number of long-term studies have
assessed the impact of DHP on the progression of chronic renal
failure in patients with non-diabetic renal disease. Eliahou and
coworkers [168, 169] have compared the effect of nisoldipine and
standard antihypertensive treatment on blood pressure and pro-
gression of renal insufficiency. Part of the patients had non-
glomerular diseases (such as polycystic kidney disease, interstitial
nephritis). Urinary protein excretion rates were not reported, but
it is likely that in part of the patients proteinuria was absent or
low. Overall, an improvement of the slope of the reciprocal of
serum creatinine was observed in the nisoldipine treated patients.
However, further analysis revealed that this improvement was
independent from the type of treatment and achieved only in
patients in whom mean arterial pressure decreased (on average
from 111 to 104 mm Hg). Apparently, the beneficial effect on the
progression of renal insufficiency was related to the blood pres-
sure decline per se. This study thus suggests that DHP calcium
channel blockers can safely be used in patients with renal diseases,
provided that blood pressure is lowered. However, in view of the
patients characteristics, such a conclusion cannot be generalized
to include patients with proteinuric renal disease. Zucchelli et al
[154, 155] have compared captopril and nifedipine in 121 non-
diabetic patients with renal insufficiency and proteinuria, who
were followed for 156 weeks. Overall, no significant differences in
renal function deterioration were observed. It should be noted,
however, that blood pressure reduction was considerable on both
drugs (blood pressures decreasing from approximately 165/100
mm Hg to 139/82 mm Hg), the majority of patients having blood
pressures below 140/80 mm Hg. Furthermore, during follow-up
more nifedipine treated patients needed hemodialysis. Although
this difference was not significant, one must be aware of the
b-error since the number of patients with a follow-up of three
years was rather small (37 vs. 31 patients in the captopril and
nifedipine group, respectively). Thus, a negative effect of the CCB
compared to the ACE inhibitor cannot be excluded. Indeed, in the
study of Piccoli et al [136] the 31 patients treated with dihydro-
pyridine calcium channel blockers had a faster decline in renal
function than the 31 patients treated with enalapril. The average
decrease in proteinuria was greater in the ACE inhibitor group
than in the DHP group. Of note, in both treatment groups only a
small blood pressure reduction was observed, mean arterial
pressure averaging approximately 110 mm Hg at the end of the
study. Altogether, the latter studies suggest that the dihydropyri-
dine CCB are less effective than the ACE inhibitors in attenuating
Fig. 4. Relationship between the change in
mean arterial pressure (MAP) and the change
in albuminuria during treatment with
dihydropyridine calcium channel blockers in
humans. (A) The results of all studies. (B) The
relationship is shown for studies in which urine
was collected in timed intervals during daytime.
Open symbols represent studies of patients with
an albuminuria of less than 500 mg/24 hours,
whereas closed symbols represent studies of
patients with an albuminuria of more than 500
mg/24 hours.
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progressive renal failure, in particular when blood pressure reduc-
tion is only modest. In non-diabetic patients data on the long-term
efficacy of non-DHP calcium channel blockers are lacking.
In diabetics two studies of more than one year have suggested
benefits from diltiazem [150] and verapamil or diltiazem [93]
during profound blood pressure reductions. In the study of
Slataper et al [150] three groups of 10 patients each were treated
with diltiazem, lisinopril and atenolol/furosemide, respectively. In
all groups mean arterial blood pressure was lowered from approx-
imately 120 to 104 mm Hg. In the diltiazem and lisinopril group
the antiproteinuric effect and the rate of decline in glomerular
filtration rate was nearly identical. In the atenolol/furosemide
group reduction of albuminuria was significantly less and the
decline in glomerular filtration rate was greater. However, in this
group the patients were older, had a slightly longer duration of
hypertension and more black patients were included. Bakris et al
[93] treated three groups with lisinopril, atenolol and verapamil,
or diltiazem during five years. The majority of patients was also
treated with furosemide. In all groups the mean arterial pressure
was reduced by approximately 16 mm Hg to 100 mm Hg. The
reduction in proteinuria and annual rate of decline in creatinine
clearance was similar in the lisinopril and verapamil/diltiazem
groups. In contrast, in the atenolol group the reduction in
proteinuria was significantly less and the decline in creatinine
clearance steeper. However, during the treatment period the
systolic blood pressure was significantly higher in the atenolol
group, which also included more black patients. Thus, both
studies suggest that during profound blood pressure reduction in
diabetic patients the beneficial effect of a treatment with vera-
pamil/diltiazem is comparable to the effect of an ACE inhibitor.
These studies do not provide definitive proof that these drugs
have additional benefits compared to beta-blockers/furosemide
treatment.
Effects of calcium channel blockers in chronic ischemic injury
The use of the immunosuppressive drug cyclosporine is ham-
pered by its nephrotoxicity. The adverse effects of cyclosporine on
the kidney are in part attributed to the afferent vasoconstriction
and ensuing ischemia [85]. Calcium channel blockers might afford
protection by attenuating this vasoconstriction. Indeed, several
studies have claimed improvement of renal function and attenu-
ation of renal histological injury when cyclosporine is combined
with a CCB [170–172]. However, definite proof of long-term
benefits has yet to come. When using calcium channel blockers
and cyclosporine in combination, one must be aware that certain
calcium channel blockers can increase the cyclosporine levels.
Verapamil, diltiazem, nicardipine and amlodipine are known to
increase the cyclosporine level, whereas no effect is seen during
concomitant treatment with nifedipine, isradipine or nitrendipine
[173].
As mentioned above, in animal experiments nifedipine attenu-
ated the renal injury caused by the NO-synthase inhibitor L-
NMMA. It has been suggested that an endogenous inhibitor of
NO might accumulate in the serum of patients with renal failure
[174]. Indeed, if such an inhibitor affects hypertension and
progression of renal failure in humans, CCBs might be advanta-
geous. However, information is too limited to allow for meaning-
ful conclusions.
CONCLUSIONS
In many animal models of progressive glomerulosclerosis cal-
cium channel blockers neither decreased proteinuria nor delayed
the progression of renal insufficiency. Some studies even reported
an increase of renal damage. These adverse effects are likely to be
explained by the preferential afferent vasodilation resulting in an
impairment of autoregulation and increased glomerular capillary
pressure.
In the animal models protection is observed only when treat-
ment is started at the onset of injury, a condition which cannot
easily be met in humans. Calcium channel blockers afford protec-
tion in models of ischemic injury caused by afferent vasocontric-
tion (cyclosporine, L-NMMA).
Also, in humans proteinuria and hypertension are the best
predictive factors of progressive renal disease, as has been shown
by the MDRD study [11]. Many reports on dihydropyridine CCBs
suggest that these antihypertensive drugs do not reduce protein-
uria. The data demonstrate an increase in albuminuria during
small blood pressure reductions, whereas only a moderate anti-
proteinuric effect is seen during profound blood pressure de-
creases.
Studies demonstrating a clear beneficial effect of dihydropyri-
dines on the progression of renal insufficiency are lacking. In fact,
the available evidence suggests that dihydropyridines may be less
effective than ACE inhibitors. Therefore, monotherapy with
dihydropyridines as first line treatment in patients with renal
insufficiency and proteinuria is not advisable.
If, on the other hand, during treatment with other antihyper-
tensive drugs such patients do not reach the target blood pressure
of 125/75 mm Hg as advocated by the MDRD study [11], addition
of a dihydropyridine CCB could be valuable. In such a case, we
suggest to closely monitor blood pressure and proteinuria. Any
increase in proteinuria should lead to a critical reassessment of
the value of the treatment with the dihydropyridine CCB.
Data on proteinuria and progression of renal function during
treatment with verapamil or diltiazem are virtually absent in
patients with non-diabetic renal disease, and prospective studies
with these drugs are urgently needed. At least in diabetic patients
beneficial effects of these classes of drugs have been suggested.
From our analysis of the effects of dihydropyridine calcium
channel blockers on proteinuria it is evident that interpretation of
the data are hampered by methodological problems. In future
studies it is important to measure protein excretion under stan-
dardized conditions (with respect to timing, posture, etc.) and in
relation to time averaged blood pressures.
ACKNOWLEDGMENT
A.J.W. Branten is supported by a grant from the Dutch Kidney
Foundation (Nierstichting Nederland No. 94.1426).
Reprint requests to Heinrich J. Kloke, M.D., Division of Nephrology,
Department of Medicine, University Hospital Nijmegen, P.O. Box 9101, 6500
HB Nijmegen, The Netherlands.
REFERENCES
1. KLAHR S, SCHREINER G, ICHIKAWA I: The progression of renal
disease. N Engl J Med 318:1657–1666, 1988
2. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein and the
progressive nature of renal disease: The role of hemodynamically
Kloke: Calcium channel blockers and renal injury1568
mediated glomerular injury in the pathogenesis of progressive glo-
merular sclerosis in aging, renal ablation, and intrinsic renal disease.
N Engl J Med 307:652–659, 1982
3. REMUZZI G, BERTANI T: Is glomerulosclerosis a consequence of
altered permeability to macromolecules? Kidney Int 38:384–394,
1990
4. D’AMICO G: The clinical role of proteinuria. Am J Kidney Dis
17(Suppl 1):48–52, 1991
5. WILLIAMS JD, COLES GA: Proteinuria - a direct cause of renal
morbidity? Kidney Int 45:443–450, 1994
6. BURTON CJ, WALLS J: Proximal tubular cell, proteinuria and tubu-
lointerstitial scarring. Nephron 68:287–293, 1994
7. EDDY AA: Experimental insights into the tubulo-interstitial disease
accompanying primary glomerular lesions. J Am Soc Nephrol 5:1273–
1287, 1994
8. BRAZY PC, STEAD WW, FITZWILLIAM JF: Progression of renal
insufficiency: Role of blood pressure. Kidney Int 35:670–674, 1989
9. WILLIAMS PS, FASS G, BONE JM: Renal pathology and proteinuria
determine progression in untreated mild/moderate chronic renal
failure. Q J Med 67:343–354, 1988
10. ALVESTRAND A, GUTIERREZ A, BUCHT H, BERGSTRO¨M J: Reduction
of blood pressure retards the progression of chronic renal failure in
man. Nephrol Dial Transplant 3:624–631, 1988
11. KLAHR S, LEVEY AS, BECK GJ, CAGGIULA AW, HUNSICKER L,
KUSEK JW, STRIKER G, FOR THE MODIFICATION OF DIET IN RENAL
DISEASE STUDY GROUP: The effects of dietary protein restriction and
blood-pressure control on the progression of chronic renal disease.
N Engl J Med 330:877–884, 1994
12. PETERSON JC, ADLER S, BURKART JM, GREENE T, HEBERT LA,
LAWRENCE G, HUNSICKER LG, KING AJ, KLAHR S, MASSRY SG,
SEIFTER JL: Blood pressure control, proteinuria, and the progression
of renal disease. The modification of diet in renal disease study. Ann
Intern Med 123:754–762, 1995
13. BAUMELOU A, BENTCHIKOU A, VRAY M, JOURDAN I, EUGENE M:
Nitrendipine in patients with renal disease. J Cardiovasc Pharmacol
9(Suppl 4):S174–S177, 1987
14. BUHLER FR: Calcium antagonists as first-choice therapy for low-
renin essential hypertension. (clinical conference) Kidney Int 36:295–
305, 1989
15. MIMRAM A, RIBSTEIN J: Angiotensin-converting enzyme inhibitors
versus calcium antagonists in the progression of renal diseases. Am J
Hypertens 7:73S—81S, 1994
16. DEMARIE BK, BAKRIS GL: Effects of different calcium antagonists on
proteinuria associated with diabetes mellitus. Ann Intern Med 113:
987–988, 1990
17. WEIDMANN P, BOEHLEN LM, DE COURTEN M: Effects of different
antihypertensive agents on human diabetic proteinuria. Nephrol Dial
Transplant 8:582–584, 1993
18. WEIDMANN P, BOEHLEN LM, DE COURTEN M, FERRARI P: Antihy-
pertensive therapy in diabetic patients. J Hum Hypert 6(Suppl
2):S23–S36, 1992
19. NORGAARD K, JENSEN T, FELDT-RASMUSSEN B: Effects of isradipine
in type I (insulin-dependent) diabetic patients with albuminuria and
normal blood pressure. J Hum Hypertens 6:145–150, 1992
20. BUHLER FR: Antihypertensive treatment according to age, plasma
renin and race. Drugs 35:495–503, 1988
21. TRIGGLE DJ: Biochemical and pharmacological differences among
calcium channel antagonists: Clinical implications, in Calcium An-
tagonists in Clinical Medicine, edited by EPSTEIN M, Philadelphia,
Hanley & Belfus, Inc., 1992, p 1
22. MORI Y, MIKALA G, VARADI G, KOBAYASHI T, KOCH S, WAKAMORI
M, SCHWARTZ A: Molecular pharmacology of voltage-dependent
calcium channels. Jpn J Pharmacol 72:83–109, 1996
23. VARADI G, MORI Y, MIKALA G, SCHWARTZ A: Molecular determi-
nants of Ca21 channel function and drug action. Trends Pharmacol
Sci 16:43–49, 1995
24. ROSSIER MF, BURNAY MM, VALLOTTON MB, CAPPONI AM: Distinct
functions of T- and L-type calcium channels during activation of
bovine adrenal glomerulosa cells. Endocrinology 137:4817–4826,
1996
25. LU HK, FERN RJ, LUTHIN D, LINDEN J, LIU LP, COHEN CJ, BARRETT
PQ: Angiotensin II stimulates T-type Ca21 channel currents via
activation of a G protein, Gi. Am J Physiol 271:C1340–C1349, 1996
26. TRIGGLE DJ: Pharmacologic and therapeutic differences among
calcium channel antagonists: Profile of mibefradil, a new calcium
antagonist. Am J Cardiol 78(Suppl 9A):7–12, 1996
27. DWORKIN LD, LEVIN RI, BENSTEIN JA, PARKER M, ULLIAN ME, KIM
Y, FEINER HD: Effects of nifedipine and enalapril on glomerular
injury in rats with deoxycorticosterone-salt hypertension. Am J
Physiol 259:F598–F604, 1990
28. DWORKIN LD, FEINER HD, PARKER M, TOLBERT E: Effects of
nifedipine and enalapril on glomerular structure and function in
uninephrectomized SHR. Kidney Int 39:1112–1117, 1991
29. DWORKIN LD, BENSTEIN JA, PARKER M, TOLBERT E, FEINER HD:
Calcium antagonists and converting enzyme inhibitors reduce renal
injury by different mechanisms. Kidney Int 43:808–814, 1993
30. ELIAHOU HE, COHEN D, HERZOG D, SHECHTER P, SERBAN I,
KAPULER S, SCHIBY G, GAVENDO S: The control of hypertension and
its effect on renal function in rat remnant kidney. Nephrol Dial
Transplant 3:38–44, 1988
31. KOBAYASHI S, HISHIDA A: Effects of a calcium antagonist, manidip-
ine, on progressive renal injury associated with mild hypertension in
remnant kidneys. J Lab Clin Med 125:572–580, 1995
32. KANNO Y, SUZUKI H, OKADA H, SARUTA T: Renal protective effects
of amlodipine on partially nephrectomized spontaneously hyperten-
sive rats fed a high-salt diet. J Cardiovasc Pharmacol 23:480–484,
1994
33. HARRIS DCH, HAMMOND WS, BURKE TJ, SCHRIER RW: Verapamil
protects against progression of experimental chronic renal failure.
Kidney Int 31:41–46, 1987
34. JARUSIRIPIPAT C, CHAN L, SHAPIRO JI, SCHRIER RW: Effect of
long-acting calcium entry blocker (anipamil) on blood pressure, renal
function and survival of uremic rats. J Pharmacol Exp Ther 260:243–
247, 1992
35. NORDLANDER M, HAVU N: Effects of chronic felodipine treatment
on renal function and morphology in SHR. Kidney Int 41(Suppl
36):S100–S105, 1992
36. FERRANTE F, ABBATE F, CIRIACO E, POLIDORI C, AMENTA F:
Protective effect of nicardipine treatment on renal microanatomical
changes in spontaneously hypertensive rats. Clin Exp Hypertens
16:415–429, 1994
37. SHUDO C, MASUDA Y, SUGITA H, FURUKAWA S, HAYASHI K, HIRATA
H, TANAKA S, TOMITA K: Renal protective effect of efonidipine
hydrochloride, a new calcium antagonist, in spontaneously hyperten-
sive rats. Gen Pharmacol 25:1567–1575, 1994
38. ARAI T, KOBAYASHI S, NAKAJIMA T, HISHIDA A: Reduction of
albuminuria by a calcium antagonist, manidipine, in rats with passive
Heymann nephritis. Jap J Nephrol 36:1216–1220, 1994
39. SHIRAKURA S, SANO J, KARASAWA A, KUBO K: Protective effect of
benidipine against the development of glomerular sclerosis in exper-
imental nephrotic syndrome. Jpn J Pharmacol 59:461–467, 1992
40. GABER L, WALTON C, BROWN S, BAKRIS G: Effects of different
antihypertensive treatments on morphologic progression of diabetic
nephropathy in uninephrectomized dogs. Kidney Int 46:161–169,
1994
41. BROWN SA, WALTON CL, CRAWFORD P, BAKRIS GL: Long-term
effects of antihypertensive regimens on renal hemodynamics and
proteinuria. Kidney Int 43:1210–1218, 1993
42. JYOTHIRMAYI GN, REDDI AS: Effect of diltiazem on glomerular
heparan sulfate and albuminuria in diabetic rats. Hypertension 21:
795–802, 1993
43. YOSHIDA K, KOHZUKI M, YASUJIMA M, KANAZAWA M, ABE K:
Effects of benidipine, a calcium antagonist, on urinary kallikrein
excretion and renal impairment in experimental diabetes. J Hypertens
14:215–222, 1996
44. AMANN K, NICHOLS C, TORNIG J, SCHWARZ U, ZEIER M, MALL G,
RITZ E: Effect of ramipril, nifedipine, and moxonidine on glomerular
morphology and podocyte structure in experimental renal failure.
Nephrol Dial Transplant 11:1003–1011, 1996
45. IRZYNIEC T, MALL G, GREBER D, RITZ E: Beneficial effect of
nifedipine and moxonidine on glomerulosclerosis in spontaneously
hypertensive rats. A micromorphometric study. Am J Hypertens
5:437–443, 1992
46. BRUNNER FP, THIEL G, HERMLE M, BOCK HA, MIHATSCH MJ:
Long-term enalapril and verapamil in rats with reduced renal mass.
Kidney Int 36:969–977, 1989
Kloke: Calcium channel blockers and renal injury 1569
47. BRUNNER FP, BOCK HA, HERMLE M, THIEL G, MIHATSCH MJ:
Control of hypertension by verapamil enhances renal damage in a rat
remnant kidney model. Nephrol Dial Transplant 6:420–427, 1991
48. TOLINS JP, RAIJ L: Comparison of converting enzyme inhibitor and
calcium channel blocker in hypertensive glomerular injury. Hyperten-
sion 16:452–461, 1990
49. PODJARNY E, BERNHEIM JL, POMERANZ A, RATHAUS M, POMERANZ
M, GREEN J, BERNHEIM J: Effect of timing of antihypertensive
therapy on glomerular injury: Comparison between captopril and
diltiazem. Nephrol Dial Transplant 8:501–506, 1993
50. JACKSON B, JOHNSTON CI: The contribution of systemic hypertension
to progression of chronic renal failure in the rat remnant kidney:
Effect of treatment with an angiotensin converting enzyme inhibitor
or a calcium inhibitor. J Hypertens 6:495–501, 1988
51. WENZEL UO, TROSCHAU G, SCHOEPPE W, HELMCHEN U, SCHWI-
ETZER G: Adverse effect of the calcium channel blocker nitrendipine
on nephrosclerosis in rats with renovascular hypertension. Hyperten-
sion 20:233–241, 1992
52. VENIANT M, HEUDES D, CLOZEL J-P, BRUNEVAL P, MENARD J:
Calcium blockade versus ACE inhibition in clipped and unclipped
kidneys of 2K–1C rats. Kidney Int 46:421–429, 1994
53. DWORKIN LD, TOLBERT E, RECHT PA, HERSCH JC, FEINER H, LEVIN
RI: Effects of amlodipine on glomerular filtration, growth, and injury
in experimental hypertension. Hypertension 27:245–250, 1996
54. GRIFFIN KA, PICKEN MM, BIDANI AK: Deleterious effects of calcium
channel blockade on pressure transmission and glomerular injury in
rat remnant kidneys. J Clin Invest 96:793–800, 1995
55. REAMS GP, VILLARREAL D, WU Z, WANG X, LUGER AM, BAUER JH:
An evaluation of the renal protective effect of manidipine in the
uninephrectomized spontaneously hypertensive rat. Am Heart J
125:620–625, 1993
56. REMUZZI A, IMBERTI O, PUNTORIEREI S, MALANCHINI B, MACCONI
D, MAGRINI L, BERTANI T, REMUZZI G: Dissociation between
antiproteinuric and anti-hypertensive effect of angiotensin convert-
ing enzyme inhibitors in rats. Am J Physiol 267:F1034–F1044, 1994
57. COOPER ME, RUMBLE JR, GIN T, LIM-JOON T: Diabetic renal
microvascular disease: The role of hypertension and ACE-inhibitors.
Clin Exp Pharmacol Physiol 19(Suppl 19):23–27, 1992
58. PERICO N, AMUCHASTEGUI CS, MALANCHINI B, BERTANI T, REMUZZI
G: Angiotensin-converting enzyme inhibition and calcium channel
blockade both normalize early hyperfiltration in experimental diabe-
tes, but only the former prevents late renal structural damage. Exp
Nephrol 2:220–228, 1994
59. ANDERSON S, RENNKE HG, BRENNER BM: Nifedipine versus fosino-
pril in uninephrectomized diabetic rats. Kidney Int 41:891–897, 1992
60. WHITTY MR, JACKSON B: Diabetic nephropathy in the rat: Differing
renal effects of an angiotensin converting enzyme inhibitor and a
calcium inhibitor. Diabetes Res 8:91–96, 1988
61. GRIFFIN KA, PICKEN M, BIDANI AK: Radiotelemetric BP monitor-
ing, antihypertensives and glomeruloprotection in remnant kidney
model. Kidney Int 46:1010–1018, 1994
62. BIDANI AK, GRIFFIN KA, PICKEN M, LANSKY DM: Continuous
telemetric blood pressure monitoring and glomerular injury in the rat
remnant kidney model. Am J Physiol 265:F391–F398, 1993
63. BIDANI AK, SCHWARTZ MM, LEWIS EJ: Renal autoregulation and
vulnera-bility to hypertensive injury in remnant kidney. Am J Physiol
252:F1003–F1010, 1987
64. FLEMING JT, PAREKH N, STEINHAUSEN M: Calcium antagonists
preferentially dilate preglomerular vessels of hydronephrotic kidney.
Am J Physiol 253:F1157–F1163, 1987
65. LOUTZENHISER R, EPSTEIN M, HORTON C: Inhibition by diltiazem of
pressure-induced afferent vasoconstriction in the isolated perfused
kidney. Am J Cardiol 59:72A–75A, 1987
66. RODICIO JL, CAMPO C, RUILOPE LM: Renal effects of calcium
antagonists. Nephrol Dial Transplant 10(Suppl 9):17–22, 1995
67. NAVAR LG, CHAMPION WJ, THOMAS CE: Effects of calcium channel
blockade on renal vascular resistance responses to changes in
perfusion pressure and angiotensin-converting enzyme inhibition in
dogs. Circ Res 58:874–881, 1986
68. OGAWA N: Effect of nicardipine on the relationship of renal blood
flow and of renal vascular resistance to perfusion pressure in dog
kidney. J Pharm Pharmacol 42:138–140, 1990
69. CARMINES PK, MITCHELL KD, NAVAR LG: Effects of calcium
antagonists on renal hemodynamics and glomerular function. Kidney
Int 41(Suppl 36):S43–S48, 1992
70. KVAM FI, IVERSEN BM, OFSTAD J: Autoregulation of glomerular
capillary pressure in SHR during successive reduction of systemic
blood pressure with antihypertensive agents. (abstract) J Am Soc
Nephrol 7:1552, 1996
71. PICKEN M, GRIFFIN K, BAKRIS G, BIDANI A: Differences in the
anti-hypertensive and glomeruloprotective efficacies of calcium
channel blockers in the remnant kidney model. (abstract) J Am Soc
Nephrol 7:1586, 1996
72. BIDANI AK, GRIFFIN KA, PICKEN M: Preservation of renal autoreg-
ulation and not blockade of renal hypertrophy mediates the glomeru-
loprotection provided by a low protein diet in the remnant kidney
model. (abstract) J Am Soc Nephrol 7:1577, 1996
73. CARMINES PK, NAVAR LG: Disparate effects of Ca channel blockade
on afferent and efferent arteriolar responses to ANG II. Am J Physiol
256:F1015–F1020, 1989
74. CONGER JD, FALK SA: KCl and angiotensin responses in isolated
renal arterioles: Effects of diltiazem and low-calcium medium. Am J
Physiol 264:F134–F140, 1993
75. WENZEL UO, HELMCHEN U, SCHOEPPE W, SCHWIETZER G: Combi-
nation treatment of enalapril with nitrendipine in rats with renovas-
cular hypertension. Hypertension 23:114–122, 1994
76. YOSHIDA Y, FOGO A, ICHIKAWA I: Glomerular hemodynamic
changes vs. hypertrophy in experimental glomerular sclerosis. Kidney
Int 35:654–660, 1989
77. MEYER TW, RENNKE HG: Progressive glomerular injury following
limited infarction in the rat. Am J Physiol 254:F856–F862, 1988
78. LAX DS, BENSTEIN JA, TOLBERT E, DWORKIN LD: Effects of salt
restriction on renal growth and glomerular injury in rats with
remnant kidneys. Kidney Int 41:1527–1534, 1992
79. DWORKIN LD: Effects of calcium antagonists on glomerular hemo-
dynamics and structure in experimental hypertension. Am J Kidney
Dis 17:89–93, 1991
80. AMANN K, TORNIG J, NICHOLS C, ZEIER M, MALL G, RITZ E: Effect
of ACE inhibitors, calcium channel blockers and their combination
on renal and extrarenal structures in renal failure. Nephrol Dial
Transplant 10(Suppl 9):33–38, 1995
81. BENSTEIN JA, FEINER HD, OHSUMI F, TOLBERT E, DWORKIN LD:
Impact of salt restriction and calcium antagonists on renal hypertro-
phy, function and sclerosis in rats with remnant kidneys (RK) and
established injury. (abstract) J Am Soc Nephrol 3:734, 1992
82. GOLIGORSKY MS, CHAIMOVITZ C, RAPAPORT J, GOLDSTEIN J, KOL R:
Calcium metabolism in uremic nephrocalcinosis: Preventive effect of
verapamil. Kidney Int 27:774–779, 1985
83. BAYLIS C, MITRUKA B, DENG A: Chronic blockade of nitric oxide
synthesis in the rat produces systemic hypertension and glomerular
damage. J Clin Invest 90:278–281, 1992
84. RIBEIRO MO, ANTUNES E, MUSCARA MN, DE NUCCI G, ZATZ R:
Nifedipine prevents renal injury in rats with chronic nitric oxide
inhibition. Hypertension 26:150–155, 1995
85. MCNALLY PG, FEEHALLY J: Pathophysiology of cyclosporin A neph-
rotoxicity: Experimental and clinical observations. Nephrol Dial
Transplant 7:791–804, 1992
86. GANSEVOORT RT, DE ZEEUW D, DE JONG PE: Long-term benefits of
the antiproteinuric effect of angiotensin-converting enzyme inhibi-
tion in nondiabetic renal disease. Am J Kidney Dis 22:202–206, 1993
87. ROSSING P, HOMMEL E, SMIDT UM, PARVING H-H: Reduction in
albuminuria predicts a beneficial effect on diminishing the progres-
sion of human diabetic nephropathy during antihypertensive treat-
ment. Diabetologia 37:511–516, 1994
88. ABBOTT K, SMITH A, BAKRIS GL: Effects of dihydropyridine calcium
antagonists on albuminuria in patients with diabetes. J Clin Pharma-
col 36:274–279, 1996
89. AUGUST P, LENZ T, LARAGH JH: Comparative renal hemodynamic
effects of lisinopril, verapamil, and amlodipine in patients with
chronic renal failure. Am J Hypertens 6:148S–154S, 1993
90. BABA T, TOMIYAMA T, MURABAYASHI S, TAKEBE K: Renal effects of
nicardipine, a calcium antagonist, in hypertensive type 2 (non-
insulin-dependent) diabetic patients with and without nephropathy.
Eur J Clin Pharmacol 38:425–429, 1990
91. BABA T, MURABAYASHI S, TAKEBE K: Comparison of the renal
effects of angiotensin converting enzyme inhibitor and calcium
Kloke: Calcium channel blockers and renal injury1570
antagonist in hypertensive type 2 (non-insulin-dependent) diabetic
patients with microalbuminuria: A randomised controlled trial.
Diabetologia 32:40–44, 1989
92. BAKRIS GL, BARNHILL BW, SADLER R: Treatment of arterial hyper-
tension in diabetic humans: Importance of therapeutic selection.
Kidney Int 41:912–919, 1992
93. BAKRIS GL, COPLEY JB, VICKNAIR N, SADLER R, LEURGANS S:
Calcium channel blockers versus other antihypertensive therapies on
progression of NIDDM associated nephropathy. Kidney Int 50:1641–
1650, 1996
94. BAKRIS GL, SMITH A: Effects of sodium intake on albumin excretion
in patients with diabetic nephropathy treated with long-acting cal-
cium antagonists. Ann Intern Med 125:201–204, 1996
95. BAKRIS GL: Effects of diltiazem or lisinopril on massive proteinuria
associated with diabetes mellitus. (see comments) Ann Intern Med
112:707–708, 1990
96. BANNISTER KM, WEAVER A, CLARKSON AR, WOODROFFE AJ: Effect
of angiotensin-converting enzyme and calcium channel inhibition on
progression of IgA nephropathy. Contrib Nephrol 111:184–192, 1995
97. BIANCHI S, BIGAZZI R, BALDARI G, CAMPESE VM: Microalbuminuria
in patients with essential hypertension: Effects of several antihyper-
tensive drugs. Am J Med 93:525–528, 1992
98. BIANCHI S, BIGAZZI R, BALDARI G, CAMPESE VM: Microalbuminuria
in patients with essential hypertension. Effects of an angiotensin
converting enzyme inhibitor and of a calcium channel blocker. Am J
Hypertens 4:291–296, 1991
99. BIANCHI S, BIGAZZI R, BALDARI G, CAMPESE VM: Long-term effects
of enalapril and nicardipine on urinary albumin excretion in patients
with chronic renal insufficiency: A 1-year follow-up. Am J Nephrol
11:131–137, 1991
100. BIGAZZI R, BIANCHI S, BALDARI D, SGHERRI G, BALDARI G,
CAMPESE VM: Long-term effects of a converting enzyme inhibitor
and a calcium channel blocker on urinary albumin excretion in
patients with essential hyperten-sion. Am J Hypertens 6:108–113,
1993
101. BILO H, KLUITMAN E, VAN BALLEGOOIE E, POTTER VAN LOON BJ,
BAKKER K, MICHELS B, GANS R, DONKER A: Long term use of
captopril or nifedipine in normotensive microalbuminuric patients
with insulin-dependent diabetes mellitus. Diabetes Res 23:115–122,
1993
102. BOUHANICK B: Equivalent effects of nicardipine and captopril on
urinary albumin excretion of type 2, non-insulin-dependent diabetic
subjects with mild to moderate hypertension. Therapie 51:41–47,
1996
103. BRETZEL RG, BOLLEN CC, MAESER E, FEDERLIN KF: Nephropro-
tective effects of nitrendipine in hypertensive type I and type II
diabetic patients. Am J Kidney Dis 21(Suppl 3):53–64, 1993
104. CHAN JC, COCKRAM CS, NICHOLLS MG, CHEUNG CK, SWAMINATHAN
R: Comparison of enalapril and nifedipine in treating non-insulin
dependent diabetes associated with hypertension: One year analysis.
Brit Med J 305:981–985, 1992
105. CORCORAN JS, PERKINS JE, HOFFBRAND BI, YUDKIN JS: Treating
hypertension in non-insulin-dependent diabetes: A comparison of
atenolol, nifedipine, and captopril combined with bendrofluazide.
Diabet Med 4:164–168, 1987
106. CREPALDI G, CARRARO A, BROCCO E, ADEZATI L, ANDREANI D,
BOMPIANI G, BRUNETTI P, FEDELE D, GIORGINO R, GIUSTINA G,
MENZINGER G, NAVALESI R, PAGANO G, TIENGO A, VILLA G,
NOSADINI R: Hypertension and non-insulin- dependent diabetes. A
comparison between an angiotensin-converting enzyme inhibitor and
a calcium antagonist. Acta Diabetol 32:203–208, 1995
107. CRUICKSHANK JK, ANDERSON NM, WADSWORTH J, YOUNG SM,
JEPSON E: Treating hypertension in black compared with white
non-insulin dependent diabetics: A double blind trial of verapamil
and metoprolol. Brit Med J 297:1155–1159, 1988
108. CRUICKSHANK JK, ANDERSON NM, WADSWORTH J, YOUNG SM,
JEPSON E: Treating hypertensive diabetics: a comparison of vera-
pamil and metoprolol in black and white patients. J Cardiovasc
Pharmacol 10(Suppl 10):S85–S86, 1987
109. ERLEY CM, HAEFELE U, HEYNE N, BRAUN N, RISLER T: Microalbu-
minuria in essential hypertension. Reduction by different antihyper-
tensive drugs. Hypertension 21:810–815, 1993
110. FERDER L, DACCORDI H, MARTELLO M, PANZALIS M, INSERRA F:
Angiotensin converting enzyme inhibitors versus calcium antagonists
in the treatment of diabetic hypertensive patients. Hypertension
19(Suppl II):II-237–II-242, 1992
111. FIORETTO P, FRIGATO F, VELUSSI M, RIVA F, MUOLLO B, CARRARO
A, BROCCO E, CIPOLLINA MR, ABATERUSSO C, TREVISAN M, ET AL:
Effects of angiotensin converting enzyme inhibitors and calcium
antagonists on atrial natriuretic peptide release and action and on
albumin excretion rate in hypertensive insulin-dependent diabetic
patients. Am J Hypertens 5:837–846, 1992
112. FOGARI R, ZOPPI A, PASOTTI C, MUGELLINI A, LUSARDI P, LAZZARI
P, CORRADI L: Comparative effects of ramipril and nitrendipine on
albuminuria in hypertensive patients with non-insulin-dependent
diabetes mellitus and impaired renal function. (see comments) J
Hum Hypertens 9:131–135, 1995
113. GIORDANO M, SANDERS LR, CASTELLINO P, CANESSA ML, DE-
FRONZO RA: Effect of alpha-adrenergic blockers, ACE inhibitors,
and calcium channel antagonists on renal function in hypertensive
non-insulin-dependent diabetic patients. Nephron 72:447–453, 1996
114. HAISA S, NORII T, TAKATORI E, GOTO A, MORIOKA S, UCHIDA K,
HIMEI H: Effects of angiotensin-converting enzyme inhibitor (alace-
pril) and calcium antagonist (nicardipine) in hypertensive non-
insulin-dependent diabetic patients with microalbuminuria. J Diabet
Compl 5:162–164, 1991
115. HARTMANN A, LUND K, HOLDAAS H, FAUCHALD P, REISAETER A,
BERG KJ: Contrasting short-term effects of nifedipine on glomerular
and tubular functions in glomerulonephritic patients. J Am Soc
Nephrol 5:1385–1390, 1994
116. HOLDAAS H, HARTMANN A, LIEN MG, NILSEN L, JERVELL J,
FAUCHALD P, ENDRESEN L, DJOSELAND O, BERG KJ: Contrasting
effects of lisinopril and nifedipine on albuminuria and tubular
transport functions in insulin dependent diabetics with nephropathy.
J Intern Med 229:163–170, 1991
117. IKEDA T, NAKAYAMA D, GOMI T, SAKURAI J, YAMAZAKI T, YUHARA
M: Captopril, an angiotensin I-converting enzyme inhibitor, de-
creases proteinuria in hypertensive patients with renal diseases.
Nephron 52:72–75, 1989
118. INSUA A, RIBSTEIN J, MIMRAN A: Comparative effect of captopril
and nifedipine in normotensive patients with incipient diabetic
nephropathy. Postgrad Med J 64(Suppl 3):59–62, 1988
119. JENKINS DA, COWAN P, PATRICK AW, CLARKE BF: Renal responses
to nifedipine and captopril in hypertensive insulin-dependent dia-
betic men: A randomized cross-over study. Nephrol Dial Transplant
8:200–205, 1993
120. JERUMS G, ALLEN TJ, TSALAMANDRIS C, COOPER ME: Angiotensin
converting enzyme inhibition and calcium channel blockade in
incipient diabetic nephropathy. The Melbourne Diabetic Nephrop-
athy Study Group. Kidney Int 41:904–911, 1992
121. JOSEFSBERG Z, ROSS SA, LEV RAN A, HWANG DL: Effects of
enalapril and nitrendipine on the excretion of epidermal growth
factor and albumin in hypertensive NIDDM patients. Diabetes Care
18:690–693, 1995
122. JUNGMANN E, MALANYN M, MORTASAWI N, UNTERSTOGER E, HAAK
T, PALITZSCH KD, SCHERBERICH J, SCHUMM DRAEGER PM, USADEL
KH: Effect of 1-year treatment with nitrendipine versus enalapril on
urinary albumin and alpha 1-microglobulin excretion in microalbu-
minuric patients with type 1 diabetes mellitus. A randomized,
single-blind comparative study. Arzneimittelforschung 44:313–317,
1994
123. JUNGMANN E, SCHUMM DRAEGER PM, NICKELSEN T, SCHEUERMANN
EH, SCHOFFLING K: [Long-term antihypertensive treatment in dia-
betes mellitus. Results with the calcium antagonist felodipine].
Fortschr Med 109:53–56, 1991
124. KIBRIYA MG, KHAN AR, RASHID HU, JASMINE F: Effect of captopril
and nifedipine on kidney function and proteinuria in non-insulin-
dependent diabetes mellitus (NIDDM) with nephropathy. Bang-
ladesh Renal J 8:48–53, 1989
125. KLOKE HJ, WETZELS JFM, VAN HAMERSVELT HW, KOENE RAP,
KLEINBLOESEM CH, HUYSMANS FTHM: Effects of nitrendipine and
cilazapril on renal hemodynamics and albuminuria in hypertensive
patients with chronic renal failure. J Cardiovasc Pharmacol 16:924–
930, 1990
126. KLOKE HJ, WETZELS JFM, KOENE RAP, HUYSMANS FTM: Effects of
Kloke: Calcium channel blockers and renal injury 1571
low dose nifedipine on urinary protein excretion rate in patients with
renal disease. J Hypertens 15(Suppl 4):S75, 1997
127. KUBO SH, CODY RJ, COVIT AB, FELDSCHUH J, LARAGH JH: The
effects of verapamil on renal blood flow, renal function, and neuro-
hormonal profiles in patients with moderate to severe hypertension.
J Clin Hypertens 2:38S–46S, 1986
128. LENZ T, MULLER FB, SOTELO JE, LARAGH JH, AUGUST P: Hemo-
dynamic responses to verapamil monotherapy in patients with renal
disease. Am J Hypertens 4:939–943, 1991
129. MELBOURNE DIABETIC NEPHROPATHY STUDY GROUP: Comparison
between perindopril and nifedipine in hypertensive and normoten-
sive patients with microalbuminuria. Brit Med J 302:210–216, 1991
130. MICKISCH O, SCHMID M, MANN JF, HELDER T, BERGEN F, RAUTER-
BERG EW, RITZ E: [Calcium antagonists in chronic renal failure.
Undesirable effects on glomerular hemodynamics?] Dtsch Med
Wochenschr 113:1546–1548, 1988
131. MORLIN C, BAGLIVO H, BOEIJINGA JK, BRECKENRIDGE AM, CLEM-
ENT D, JOHNSTON GD, KLEIN W, KRAMER R, LUCCIONI R, MEURER
KA, RICHARDSON PJ, ROSENTHAL J, SIX R, WITZGALL H: Compar-
ative trial of lisinopril and nifedipine in mild to severe essential
hypertension. J Cardiovasc Pharmacol 9(Suppl 3):S49–52, 1987
132. NORGAARD K, JENSEN T, CHRISTENSEN P, FELDT RASMUSSEN B: A
comparison of spirapril and isradipine in patients with diabetic
nephropathy and hypertension. Blood Press 2:301–308, 1993
133. MCDONNELL MJ, ROWE BR, LAWSON N, HORTON A, GYDE OH,
BARNETT AH: Comparison of the effects of an angiotensin convert-
ing enzyme inhibitor and a calcium antagonist in hypertensive,
macroproteinuric diabetic patients: A randomised double-blind
study. J Hum Hypertens 7:333–339, 1993
134. OKAMURA M, KANAMAYAMA Y, NEGORO N, INOUE T, TAKEDA T:
Long-term effects of calcium antagonists and angiotensin-converting
enzyme inhibitors in patients with chronic renal failure of IgA
nephropathy. Contrib Nephrol 90:161–165, 1991
135. PERSSON B, ANDERSSON OK, WYSOCKI M, HEDNER T, KARLBERG B:
Calcium antagonism in essential hypertension: Effect on renal
haemodynamics and microalbuminuria. J Intern Med 231:247–252,
1992
136. PICCOLI A, FAVARO E, PIVA M, BISETTO F, CALZAVARA P, ARDUINI
R, NORDIO M, STOPPA F, RONCALI D, PILLON L: The progression
rate of chronic renal failure with hypertension and proteinuria can be
slowed by treatment with angiotensin converting enzyme inhibitors.
Curr Ther Res 53:309–315, 1993
137. RANIERI G, ANDRIANI A, LAMONTANARA G, DE CESARIS R: Effects
of lisinopril and amlodipine on microalbuminuria and renal function
in patients with hypertension. Clin Pharmacol Ther 56:323–330, 1994
138. REAMS G, LAU A, KNAUS V, BAUER JH: The effect of nifedipine
GITS on renal function in hypertensive patients with renal insuffi-
ciency. J Clin Pharmacol 31:468–472, 1991
139. REAMS GP, LAU A, BAUER JH: Short-term and long-term renal
response to nifedipine monotherapy. Am J Hypertens 2:188–190,
1989
140. REAMS GP, LAU A, HAMORY A, BAUER JH: Amlodipine therapy
corrects renal abnormalities encountered in the hypertensive state.
Am J Kidney Dis 10:446–451, 1987
141. RICHARDSON PJ, MEANY B, BRECKENRIDGE AM, GRIMMER SF,
JOHNSTON GD, KONDOWE G: Lisinopril in essential hypertension: A
six month comparative study with nifedipine. J Hum Hypertens
1:175–179, 1987
142. ROMERO R, SALINAS I, LUCAS A, TEIXIDO J, AUDI L, SANMARTI A:
Comparative effects of captopril versus nifedipine on proteinuria and
renal function of type 2 diabetic patients. Diabetes Res Clin Pract
17:191–198, 1992
143. RUGGENENTI P, MOSCONI L, BIANCHI L, CORTESI L, CAMPANA M,
PAGANI G, MECCA G, REMUZZI G: Long-term treatment with either
enalapril or nitrendipine stabilizes albuminuria and increases glo-
merular filtration rate in non-insulin-dependent diabetic patients.
Am J Kidney Dis 24:753–761, 1994
144. RUILOPE LM, ARAQUE A, LAHERA V, SUAREZ C: Antihypertensive
effect of nitrendipine in the hypertensive patient with renal impair-
ment. Ren Fail 15:359–363, 1993
145. RUILOPE LM, ALCAZAR JM, HERNANDEZ E, PRAGA M, LAHERA V,
RODICIO JL: Long-term influences of antihypertensive therapy on
microalbuminuria in essential hypertension. Kidney Int 45(Suppl
45):S171–S173, 1994
146. SCHMITZ A, PEDERSEN MM, MOLLER A, CHRISTIANSEN JS, MO-
GENSEN CE: Some aspects of antihypertensive and diuretic treatment
in noninsulin-dependent diabetic patients. J Diabet Compl 4:79–81,
1990
147. SCHMITZ A, PEDERSEN MM, MOGENSEN CE: Effects of felodipine on
urinary albumin excretion and metabolic control in hypertensive
non-insulin-dependent diabetics. Am J Hypertens 3:611–617, 1990
148. SCHNACK C, CAPEK M, BANYAI M, KAUTZKY WILLER A, PRAGER R,
SCHERNTHANER G: Long-term treatment with nifedipine reduces
urinary albumin excretion and glomerular filtration rate in normo-
tensive type 1 diabetic patients with microalbuminuria. Acta Diabetol
31:14–18, 1994
149. SIEWERT DELLE A, LJUNGMAN S, HARTFORD M, WIKSTRAND J:
Effects of intensified blood-pressure reduction on renal function and
albumin excretion in primary hypertension. Addition of felodipine or
ramipril to long-term treatment with beta-blockade. Am J Hypertens
8:113–123, 1995
150. SLATAPER R, VICKNAIR N, SADLER R, BAKRIS GL: Comparative
effects of different antihypertensive treatments on progression of
diabetic renal disease. Arch Intern Med 153:973–980, 1993
151. STORNELLO M, VALVO EV, SCAPELLATO L: Hemodynamic, renal,
and humoral effects of the calcium entry blocker nicardipine and
converting enzyme inhibitor captopril in hypertensive type II diabetic
patients with nephropathy. J Cardiovasc Pharmacol 14:851–855, 1989
152. VELUSSI M, BROCCO E, FRIGATO F, ZOLLI M, MUOLLO B, MAIOLI M,
CARRARO A, TONOLO G, FRESU P, CERNIGOI AM, FIORETTO P,
NOSADINI R: Effects of cilazapril and amlodipine on kidney function
in hypertensive NIDDM patients. Diabetes 45:216–222, 1996
153. ZANETTI ELSHATER F, PINGITORE R, BERETTA PICCOLI C, RIESEN
W, HEINEN G: Calcium antagonists for treatment of diabetes-
associated hypertension. Metabolic and renal effects of amlodipine.
Am J Hypertens 7:36–45, 1994
154. ZUCCHELLI P, ZUCCALA A, BORGHI M, FUSAROLI M, SASDELLI M,
STALLONE C, SANNA G, GAGGI R: Long-term comparison between
captopril and nifedipine in the progression of renal insufficiency.
Kidney Int 42:452–458, 1992
155. ZUCHELLI P, ZUCCALA A, GAGGI R: Comparison of the effects of
ACE inhibitors and calcium channel blockers on the progression of
renal failure. Nephrol Dial Transplant 10(Suppl 9):46–51, 1995
156. SHIHABI ZK, KONEN JC, O’CONNOR ML: Albuminuria vs urinary
total protein for detecting chronic renal disorders. Clin Chem
37:621–624, 1991
157. GANSEVOORT RT, APPERLOO AJ, HEEG JE, DE JONG PE, DE ZEEUW
D: The antiproteinuric effect of antihypertensive agents in diabetic
nephropathy. Arch Intern Med 152:2137–2138, 1992
158. WEIDMANN P, SCHNEIDER M, BO¨HLEN L: Therapeutic efficacy of
different antihypertensive drugs in human diabetic nephropathy: An
updated meta-analysis. Nephrol Dial Transplant 10(Suppl 9):39–45,
1995
159. SLUITER HE, WETZELS JFM, HUYSMANS FTHM, KOENE RAP: The
natriuretic effect of the dihydropyridine calcium antagonist felodip-
ine: A placebo-controlled study involving intravenous angiotensin II
in normotensive volunteers. J Cardiovasc Pharmacol 10(Suppl 10):
S154–S161, 1987
160. WETZELS JFM, WILTINK PG, HOITSMA AJ, HUYSMANS FTHM,
KOENE RAP: Diuretic and natriuretic effects of nifedipine in healthy
persons. Br J clin Pharmacol 25:547–553, 1988
161. KRUSELL LR, CHRISTENSEN CK, LEDERBALLE PEDERSEN O: Acute
natriuretic effect of nifedipine in hypertensive patients and normo-
tensive controls - A proximal tubular effect? Eur J Clin Pharmacol
32:121–126, 1987
162. GARINI G, MAZZI A, BUZIO C, MUTTI A, ALLEGRI L, SAVAZZI G,
BORGHETTI A: Renal effects of captopril, indomethacin and nifedi-
pine in nephrotic patients after an oral protein load. Nephrol Dial
Transplant 11:628–634, 1996
163. NICHOLSON JP, RESNICK LM, LARAGH JH: The antihypertensive
effect of verapamil at extremes of dietary sodium intake. Ann Intern
Med 107:329–334, 1987
Kloke: Calcium channel blockers and renal injury1572
164. CAPPUCCIO FP, MARKANDU ND, MACGREGOR GA: Calcium antag-
onists and sodium balans: Effect of changes in sodium intake and the
addition of a thiazide diuretic on the blood pressure lowering effect
of nifedipine. J Cardiovasc Pharmacol 10(Suppl 10):S57–S60, 1987
165. REDON-MAS J, ABELLAN-ALEMAN J, ARANDRA-LARA P, DE LA
FIGUERA-VON WICHMANN M, LUQUE-OTERO M, RODICIO-DIAZ JL,
RUILOPE-URIOSTE LM, VELASCO-QUINTANA J: Antihypertensive ac-
tivity of verapamil: Impact of dietary sodium. J Hypertens 11:665–671,
1993
166. MAN in ’t Veld AJ: Calcium antagonists in hypertension. Am J Med
86(Suppl 4A):6–14, 1989
167. SCHOEN RE, FRISHMAN WH, SHAMOON H: Hormonal and metabolic
effects of calcium channel antagonists in man. Am J Med 84:492–504,
1988
168. BLAU A, HERZOG D, SHECHTER P, SACHS D, ELIAHOU HE: Calcium
channel blocker nisoldipine in chronic renal failure. Renal Failure
12:113–119, 1990
169. ELIAHOU HE, COHEN D, BEN-DAVID A, HERZOG D, SERBAN I,
GAVENDO S, KAPULER S, KOGAN N, HELLBERG B: The calcium
channel blocker nisoldipine delays progression of chronic renal
failure in humans (preliminary communication). Cardiovasc Drugs
Ther 1:523–528, 1988
170. MCCULLOCH TA, HARPER SJ, DONNELLY PK, MOORHOUSE J, BELL
PRF, WALLS J, FEEHALLY J, FURNESS PN: Influence of nifedipine on
interstitial fibrosis in renal transplant allografts treated with cyclo-
sporin A. J Clin Pathol 47:839–842, 1994
171. RUGGENENTI P, PERICO N, MOSCONI L, GASPARI F, BENIGNI A,
AMUCHASTEGUI CS, BRUZZI I, REMUZZI G: Calcium channel block-
ers protect transplant patients from cyclosporin-induced daily renal
hypoperfusion. Kidney Int 43:706–711, 1993
172. RODICIO JL, MORALES JM, RUILOPE LM: Lipophilic dihydropyri-
dines provide renal protection from cyclosporin toxicity. J Hyperten-
sion 11(Suppl 6):S21–S25, 1993
173. PESAVENTO TE, JONES PA, JULIAN BA, CURTIS JJ: Amlodipine
increases cyclosporine levels in hypertensive renal transplant pa-
tients: Results of a prospective study. J Am Soc Nephrol 7:831–835,
1996
174. VALLANCE P, LEONE A, CALVER A, COLLIER J, MONCADA S: Accu-
mulation of an endogenous inhibitor of nitric oxide synthesis in
chronic renal failure. Lancet 339:572–575, 1992
Kloke: Calcium channel blockers and renal injury 1573
